331 related articles for article (PubMed ID: 30104481)
21. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
Chen J; Zhao KN; Li R; Shao R; Chen C
Curr Med Chem; 2014; 21(26):3070-80. PubMed ID: 24735369
[TBL] [Abstract][Full Text] [Related]
22. Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.
Haines K; Huang GS
Cancer Res; 2019 Aug; 79(16):4009-4010. PubMed ID: 31416848
[TBL] [Abstract][Full Text] [Related]
23. Multikinase inhibitors: a new option for the treatment of thyroid cancer.
Gild ML; Bullock M; Robinson BG; Clifton-Bligh R
Nat Rev Endocrinol; 2011 Aug; 7(10):617-24. PubMed ID: 21862995
[TBL] [Abstract][Full Text] [Related]
24. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
[TBL] [Abstract][Full Text] [Related]
25. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells.
Mukai Y; Wang CY; Rikitake Y; Liao JK
Am J Physiol Heart Circ Physiol; 2007 Apr; 292(4):H1937-42. PubMed ID: 17172275
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.
Liu L; Wang H; Cui J; Zhang Q; Zhang W; Xu W; Lu H; Liu S; Shen S; Fang F; Li L; Yang W; Zhuang Z; Li J
Cell Physiol Biochem; 2018; 50(1):317-331. PubMed ID: 30282066
[TBL] [Abstract][Full Text] [Related]
27. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
[TBL] [Abstract][Full Text] [Related]
28. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.
Diver EJ; Foster R; Rueda BR; Growdon WB
Oncologist; 2015 Sep; 20(9):1058-68. PubMed ID: 26099744
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
[TBL] [Abstract][Full Text] [Related]
31. Mechanical loading stimulates chondrogenesis via the PKA/CREB-Sox9 and PP2A pathways in chicken micromass cultures.
Juhász T; Matta C; Somogyi C; Katona É; Takács R; Soha RF; Szabó IA; Cserháti C; Sződy R; Karácsonyi Z; Bakó E; Gergely P; Zákány R
Cell Signal; 2014 Mar; 26(3):468-82. PubMed ID: 24333667
[TBL] [Abstract][Full Text] [Related]
32. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
33. PP2A regulates upstream members of the c-jun N-terminal kinase mitogen-activated protein kinase signaling pathway.
Zhao B; Sun L; Haas M; Denenberg AG; Wong HR; Shanley TP
Shock; 2008 Feb; 29(2):181-8. PubMed ID: 17693927
[TBL] [Abstract][Full Text] [Related]
34. SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Aguilar-Valdés A; Noriega LG; Tovar AR; Ibarra-Sánchez MJ; Sosa-Hernández VA; Maravillas-Montero JL; Martínez-Aguilar J
Biochem Biophys Res Commun; 2021 May; 552():23-29. PubMed ID: 33740661
[TBL] [Abstract][Full Text] [Related]
35. New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?
Rodriguez-Freixinos V; Karakasis K; Oza AM
Curr Oncol Rep; 2016 Apr; 18(4):23. PubMed ID: 26922329
[TBL] [Abstract][Full Text] [Related]
36. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
[TBL] [Abstract][Full Text] [Related]
37. Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies.
Kyo S; Nakayama K
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842547
[TBL] [Abstract][Full Text] [Related]
38. Basal and IGF-I-dependent regulation of potassium channels by MAP kinases and PI3-kinase during eccentric cardiac hypertrophy.
Teos LY; Zhao A; Alvin Z; Laurence GG; Li C; Haddad GE
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H1834-45. PubMed ID: 18757484
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of protein kinase (PK) Cδ attenuates methamphetamine-induced dopaminergic toxicity via upregulation of phosphorylation of tyrosine hydroxylase at Ser40 by modulation of protein phosphatase 2A and PKA.
Dang DK; Duong CX; Nam Y; Shin EJ; Lim YK; Jeong JH; Jang CG; Nah SY; Nabeshima T; Kim HC
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):192-201. PubMed ID: 25400014
[TBL] [Abstract][Full Text] [Related]
40. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor.
Yart A; Laffargue M; Mayeux P; Chretien S; Peres C; Tonks N; Roche S; Payrastre B; Chap H; Raynal P
J Biol Chem; 2001 Mar; 276(12):8856-64. PubMed ID: 11134009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
